Norcantharidin tablets
Function and Efficacy
In vitro animal tests showed that this product had a destructive or inhibitory effect on the morphology or proliferation of liver cancer BEL-7402, esophageal cancer CaEs-17, laryngeal cancer SMMC-7721, cervical cancer Hela and other cell lines. In vivo tests showed a certain inhibitory effect on mouse Ehrlich ascites carcinoma, sarcoma 180 and solid liver cancer. It can increase the respiratory control rate and lysosomal enzyme activity of tumor cell microsomes of ascites liver cancer H22 mice, inhibit cancer cell DNA synthesis, and destroy cancer cell skeleton and ultrastructure. It interferes with cancer cell division, blocks it in the M phase, and affects its cycle speed, destroys the cancer cell skeleton (microfilaments, microtubules), affects the ultrastructure of cancer cells, causes damage to mitochondria, microvilli and plasma membrane, blocks the M phase of the cell division cycle, and interferes with cancer cell division.
Ingredients
The main ingredient of this product is norcantharidin, and its chemical name is: exo-1:2-cis-3:6-oxo-hexahydrophthalic anhydride. Molecular formula: C8H8O4 Molecular weight: 168.15
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| NorcantharidinIngredients |
It has a destructive or inhibitory effect on the morphology or proliferation of liver cancer BEL-7402, esophageal cancer CaEs-17, laryngeal cancer SMMC-7721, cervical cancer Hela and other cell lines; it has a certain inhibitory effect on mouse Ehrlich ascites carcinoma, sarcoma 180 and solid liver cancer; it can increase the respiratory control rate and lysosomal enzyme activity of the tumor cell microsomes of ascites liver cancer H22 mice, inhibit cancer cell DNA synthesis, and destroy the cancer cell skeleton and ultrastructure; interfere with cancer cell division, block it in the M phase, and affect its cycle speed, destroy the cancer cell skeleton (microfilaments, microtubules), affect the ultrastructure of cancer cells, lead to damage to mitochondria, microvilli and plasma membrane, block the M phase of the cell division cycle and interfere with cancer cell division. More |
5442-12-6 | 3 |
Appearance
This product is a sugar-coated tablet, which appears white after removing the coating.
Indication
It is suitable for patients with liver cancer, esophageal cancer, stomach and cardia cancer, as well as leukocytopenia, hepatitis, cirrhosis, and hepatitis B virus carriers.
Usage and Dosage
Oral administration. 5-15 mg once, 3 times a day. Start with a small dose and gradually increase the dose. A higher dose can be used for advanced patients, and a reduced dose can be used for children. The course of treatment is one month, and generally 3 courses can be maintained. This product can be used as a preoperative medication or in combined chemotherapy. This product can be used alternately with sodium norcantharidin injection. However, it is not advisable to use the drugs together at the same time.
Adverse Reactions
Some patients may experience symptoms such as nausea, vomiting, and dizziness, which can disappear on their own by stopping the medication, reducing the dosage, or taking symptomatic treatment.
Precautions
Not yet clear.
Special Population Medication
Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.
Drug Interactions
Not yet clear.
Storage
Keep sealed.
Packaging Specification
5mg
Validity Period
Tentative 24 months
Manufacturer
Sinopharm A-Think Pharmaceutical Co., Ltd.
-
Founded in:
1997-12-10 -
Address:
No. 111, Yixin Road, Shuangyang Economic Development Zone, Changchun -
Tax NO.:
912201012440638092 -
Registered Funds:
100 million yuan -
Website:
-
Email: